NanoString Technologies Enters Into Collaboration Agreement With Medivation …

NanoString Technologies Enters Into Collaboration Agreement With Medivation …

"Triple negative breast cancer has no recognized target and standard therapy is therefore cytotoxic chemotherapy. This diagnostic has the potential to identify patients with triple negative breast cancer appropriate for treatment with enzalutamide. We

(Visited 4 times, 1 visits today)
9
Like
Save

Comments

Comments are disabled for this post.